Board Elects Marvyn Robar as First Independent,
Non-Executive Chairman
HALIFAX,
May 6, 2014 /CNW/ - MedMira
Inc. (TSXV: MIR) announced today that its Board of
Directors appointed Marvyn Robar and
Colin MacGillivray as Directors to
serve until the next annual shareholder meeting. Dr.
Shou-Ching Tang retired from the
Board of Directors after 12 years of service. The Board
thanks Dr. Tang for his services and the guidance he provided to
MedMira during his tenure as a member of the Board. These
changes were effective May 2,
2014.
The Board elected Mr. Robar as the Company's
first non-executive Chairman. Hermes
Chan, CEO of MedMira, who served as interim Chairman, will
remain as the member of the Board. The appointment of Mr. Robar,
supports the Board's commitment to the advancement of MedMira's
corporate governance practices and policies and enables the
implementation of industry best practices within the Company.
"The diverse industry experience and backgrounds
of both our new Chairman and new director complements the expertise
of our other Board members. Being able to engage such
respected independent directors further aligns us with industry
best practices in corporate governance and positions us well to
build upon our successes," said Hermes
Chan, CEO, MedMira.
Mr. Robar brings extensive experience to the
role of Chairman of Board with over 35 years in both the private
and public sectors. Prior to his retirement from the Government of
Nova Scotia 2013, Mr. Robar served
as the Vice President, Investment, Department of Economic and Rural
Development and Tourism, in charge of the $700 million economic development fund and as
President of the Nova Scotia Strategic Opportunities Fund Inc., a
$250 million investment fund.
In this role, Mr. Robar had the opportunity to work with many of
Nova Scotia's largest companies as
well as a range of small and medium sized enterprises. He
routinely provided advice and recommendations to the Executive
Council of the Province of Nova
Scotia, ministers, and deputy ministers across a broad range
of departments on files and portfolios. After completing a
BSc in chemistry/math and working as a chemist at the Nova Scotia
Research Foundation, Mr. Robar returned to Dalhousie University, obtained an MBA and
subsequently, went on to join PricewaterhouseCoopers and earn his
Chartered Accountancy designation.
"I look forward to working closely with other
experienced Board members, Hermes, and his management team as we
continue the Company's focus on innovation and revenue generation,"
said Marvyn Robar, Chairman of
MedMira. "MedMira is a company that is reinventing the rapid
diagnostics sector with its distinct technology and the Board is
fully committed to guiding this Company forward and delivering on
its promise of increasing shareholder value through strategic
growth."
The Board also appointed Colin MacGillivray as a Director. Dr.
MacGillivray has over 20 years of experience including finance and
operating experience in life sciences across multiple geographies
with Elan Pharmaceuticals Inc., Lundbeck Inc. (the US subsidiary of
H. Lundbeck A/S, Denmark) and
Biolytical Laboratories, along with broader experience from a range
of other industries. Dr. MacGillivray is a Member of the
Institute of Chartered Accountants in England & Wales having qualified with
PricewaterhouseCoopers. He received his Ph.D. from the Department
of Animal & Plant Sciences, University of Sheffield following undergraduate studies at
the University of Edinburgh.
About MedMira
MedMira is a leading developer and manufacturer
of vertical flow rapid diagnostics. The Company's tests provide
hospitals, labs, clinics and individuals with instant diagnosis for
diseases such as HIV and hepatitis C in just three easy steps. The
Company's tests are sold under the Reveal®,
Multiplo™ and Miriad™ brands in global markets. Based on its
patented Rapid Vertical Flow Technology™, MedMira's rapid HIV test
is the only one in the world to achieve regulatory approvals in
Canada, the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For
more information visit medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MedMira Inc.